Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vyteris

This article was originally published in Start Up

Executive Summary

Becton Dickinson's spin-off, Vyteris, has big plans for its iontophoresis transdermal drug delivery system, which actively pressures molecules to go into the body over time. Vyteris has chosen to seek approval of its use first with lidocaine, a powerful, fast-acting local anesthetic, which has been on the market for years. While it works well to desensitize skin prior to minor surgery or injection, its use is limited because it takes too long to be effective for widespread applications and doesn't go deep enough under the skin. Vyteris' transdermal lidocaine system addresses these shortcomings and has the potential to expand substantially lidocaine's market.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC090399

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel